• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Cogent Biosciences Inc. (Amendment)

    2/14/24 4:11:49 PM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $COGT alert in real time by email
    SC 13G/A 1 p24-0505sc13ga.htm COGENT BIOSCIENCES, INC.
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
     

    Cogent Biosciences, Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)
     

    19240Q201

    (CUSIP Number)
     

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ¨ Rule 13d-1(b)
    ý Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 8 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 

     

     

     

    CUSIP No. 19240Q20113G/APage 2 of 8 Pages

     

    1

    NAME OF REPORTING PERSON

     

    Point72 Asset Management, L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    5,191,448

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    5,191,448

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    5,191,448

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.0%

    12

    TYPE OF REPORTING PERSON

    PN

             

     

     

    CUSIP No. 19240Q20113G/APage 3 of 8 Pages

     

     

    1

    NAME OF REPORTING PERSON

     

    Point72 Capital Advisors, Inc.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    5,191,448

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    5,191,448

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    5,191,448

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.0%

    12

    TYPE OF REPORTING PERSON

    CO

             

     

     

    CUSIP No. 19240Q20113G/APage 4 of 8 Pages

     

     

    1

    NAME OF REPORTING PERSON

     

    Cubist Systematic Strategies, LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    52,175

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    52,175

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    52,175

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.1%

    12

    TYPE OF REPORTING PERSON

    OO

             

     

     

    CUSIP No. 19240Q20113G/APage 5 of 8 Pages

     

     

    1

    NAME OF REPORTING PERSON

     

    Steven A. Cohen

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    5,243,623

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    5,243,623

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    5,243,623

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.1%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     

    CUSIP No. 19240Q20113G/APage 6 of 8 Pages

     

     

    Item 1(a). Name of Issuer.
      Cogent Biosciences, Inc. (the “Issuer”).

     

    Item 1(b). Address of Issuer's Principal Executive Offices.
      275 Wyman Street, 3rd floor, Waltham, Massachusetts 02451.

     

    Item 2(a). Name of Person Filing.
      This statement is filed by: (i) Point72 Asset Management, L.P. (“Point72 Asset Management”) with respect to shares of common stock, par value $0.001 per share (“Shares”), of the Issuer held by Point72 Associates, LLC, an investment fund it manages (“Point72 Associates”); (ii) Point72 Capital Advisors, Inc. (“Point72 Capital Advisors Inc.”) with respect to Shares held by Point72 Associates; (iii) Cubist Systematic Strategies, LLC (“Cubist Systematic Strategies”) with respect to Shares held by an investment fund it manages; and (iv) Steven A. Cohen (“Mr. Cohen”) with respect to Shares beneficially owned by Point72 Asset Management, Point72 Capital Advisors Inc., and Cubist Systematic Strategies.
       
      Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic Strategies, and Mr. Cohen have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 99.1, pursuant to which they have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Act.

     

    Item 2(b). Address of Principal Business Office.
      The address of the principal business office of (i) Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902; and (ii) Cubist Systematic Strategies is 55 Hudson Yards, New York, NY 10001.

     

    Item 2(c). Place of Organization.
      Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation. Cubist Systematic Strategies is a Delaware limited liability company.  Mr. Cohen is a United States citizen.

     

    Item 2(d). Title of Class of Securities.
      Common Stock, par value $0.001 per share.

     

    Item 2(e). CUSIP Number.
      19240Q201

     

    Item 3. If this Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b), or (c), check whether the Person Filing is a:
      Not applicable.

     

    Item 4. Ownership.
      The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.  Such information is as of the close of business on December 31, 2023.

     

     

    CUSIP No. 19240Q20113G/APage 7 of 8 Pages

     

     

      Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic Strategies, and Mr. Cohen own directly no Shares. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by Point72 Associates. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management. Pursuant to an investment management agreement, Cubist Systematic Strategies maintains investment and voting power with respect to the securities held by an investment fund it manages.  Mr. Cohen controls each of Point72 Asset Management, Point72 Capital Advisors Inc., and Cubist Systematic Strategies.   The filing of this statement should not be construed as an admission that any of the foregoing persons or any reporting person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein.

     

    Item 5. Ownership of Five Percent or Less of a Class.
      If this statement is being filed to report the fact that as of the date hereof the Reporting Person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [ ].

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
      Point72 Associates has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5 percent of the outstanding Shares.  

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
      Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.
      Not applicable.

     

    Item 9. Notice of Dissolution of Group.
      Not applicable.

     

    Item 10. Certification.
      By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    CUSIP No. 19240Q20113G/APage 8 of 8 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

     

    Date: February 14, 2024  
      POINT72 ASSET MANAGEMENT, L.P.
       
      By: /s/ Jason M. Colombo
      Name:  Jason M. Colombo
      Title:    Authorized Person
       
       
      POINT72 CAPITAL ADVISORS, INC.
       
      By: /s/ Jason M. Colombo
      Name:  Jason M. Colombo
      Title:    Authorized Person
       
       
      CUBIST SYSTEMATIC STRATEGIES, LLC
       
      By: /s/ Jason M. Colombo
      Name:  Jason M. Colombo
      Title:    Authorized Person
       
      STEVEN A. COHEN
       
      By: /s/ Jason M. Colombo
      Name:  Jason M. Colombo
      Title:    Authorized Person

     

    Get the next $COGT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $COGT

    DatePrice TargetRatingAnalyst
    11/10/2025$40.00Hold → Buy
    Stifel
    11/10/2025$38.00Neutral → Outperform
    Wedbush
    10/16/2025$16.00Hold
    Stifel
    9/3/2025$30.00Strong Buy
    Raymond James
    3/7/2025$17.00Sector Outperform
    Scotiabank
    12/11/2024Buy → Hold
    Needham
    2/26/2024$14.00 → $8.00Outperform → Neutral
    Robert W. Baird
    2/8/2024$11.00Buy
    Citigroup
    More analyst ratings

    $COGT
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Cogent Biosciences Inc.

    SCHEDULE 13G/A - Cogent Biosciences, Inc. (0001622229) (Subject)

    1/30/26 1:26:34 PM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Cogent Biosciences Inc.

    8-K - Cogent Biosciences, Inc. (0001622229) (Filer)

    12/8/25 4:05:52 PM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cogent Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

    8-K - Cogent Biosciences, Inc. (0001622229) (Filer)

    11/18/25 4:09:49 PM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COGT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual Meeting

    WALTHAM, Mass. and BOULDER, Colo., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced multiple upcoming posters highlighting bezuclastinib results from the SUMMIT trial in NonAdvanced Systemic Mastocytosis (NonAdvSM) patients at the 2026 American Academy of Allergy Asthma & Immunology Annual Meeting (AAAAI) being held in Philadelphia, PA, February 27-March 2, 2026. In December 2025, Cogent announced that the company submitted its New Drug Application for bezuclastinib in NonAdvSM to the U.S. Food and Drug Administration. The submission is based on posi

    2/10/26 8:00:00 AM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST)

    -   Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in April 2026 WALTHAM, Mass. and BOULDER, Colo., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for bezuclastinib in combination with sunitinib for patients with Gastrointestinal Stromal Tumors (GIST) who have received prior treatment with imatinib.  "We are excited to announce this Breakthrough Therapy Designat

    1/26/26 8:00:00 AM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR)

    -  PEAK trial first ever study to demonstrate statistical significance over an active comparator in GIST patients, with bezuclastinib plus sunitinib combination demonstrating mPFS of 16.5 months and ORR of 46% in patients who had received prior treatment with imatinib  -  Cogent is expected to initiate the RTOR process immediately; completion of the PEAK NDA submission expected in April 2026 WALTHAM, Mass. and BOULDER, Colo., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that the U.S. Food and Drug Administration (FDA) has agreed to accept its Ne

    1/20/26 8:00:00 AM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COGT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fairmount Funds Management Llc sold $127,400,000 worth of shares (3,500,000 units at $36.40) (SEC Form 4)

    4 - Cogent Biosciences, Inc. (0001622229) (Issuer)

    1/22/26 8:09:39 PM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Ferrante Karen Jean

    4 - Cogent Biosciences, Inc. (0001622229) (Issuer)

    1/5/26 4:01:03 PM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Green John L. sold $2,978,360 worth of shares (77,000 units at $38.68), decreasing direct ownership by 37% to 131,834 units (SEC Form 4)

    4 - Cogent Biosciences, Inc. (0001622229) (Issuer)

    12/30/25 4:01:06 PM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COGT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cogent Biosciences upgraded by Stifel with a new price target

    Stifel upgraded Cogent Biosciences from Hold to Buy and set a new price target of $40.00

    11/10/25 11:01:45 AM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cogent Biosciences upgraded by Wedbush with a new price target

    Wedbush upgraded Cogent Biosciences from Neutral to Outperform and set a new price target of $38.00

    11/10/25 10:13:55 AM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel initiated coverage on Cogent Biosciences with a new price target

    Stifel initiated coverage of Cogent Biosciences with a rating of Hold and set a new price target of $16.00

    10/16/25 8:24:32 AM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COGT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fairmount Funds Management Llc bought $24,999,993 worth of shares (2,777,777 units at $9.00) (SEC Form 4)

    4 - Cogent Biosciences, Inc. (0001622229) (Issuer)

    7/14/25 4:30:37 PM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Commercial Officer Pinnow Cole bought $332,412 worth of shares (43,750 units at $7.60), increasing direct ownership by 2,085% to 45,848 units (SEC Form 4)

    4 - Cogent Biosciences, Inc. (0001622229) (Issuer)

    1/15/25 7:00:04 AM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COGT
    Leadership Updates

    Live Leadership Updates

    View All

    Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer

    WALTHAM, Mass. and BOULDER, Colo., May 23, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Cole Pinnow as Chief Commercial Officer. Mr. Pinnow is a leader in the biopharmaceutical industry with an impressive track record in commercial strategy, including several successful product launches. At Cogent, he will be responsible for building and leading the commercial team including sales, marketing, access, and commercial operations. A key priority will be preparing the company for the potential commercial launch of bezuclastinib, for patients

    5/23/24 5:05:00 PM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cogent Biosciences Appoints Rachael Easton, MD, Ph.D., VP, Head of Clinical Development

    WALTHAM, Mass. and BOULDER, Colo., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Rachael Easton, MD, Ph.D., Vice President, Head of Clinical Development. "We are pleased to welcome Dr. Easton to Cogent as we continue to develop bezuclastinib in Systemic Mastocytosis and GIST," said Andrew Robbins, the company's President and Chief Executive Officer. "Dr. Easton is an accomplished physician-scientist who brings a wealth of experience in both early and late-stage clinical development across multiple therapeutic areas. Her backgrou

    11/28/22 4:15:00 PM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cogent Biosciences Appoints Evan Kearns as Chief Legal Officer

    CAMBRIDGE, Mass. and BOULDER, Colo., May 3, 2021 /PRNewswire/ -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Evan Kearns as Chief Legal Officer. In his new role, Mr. Kearns will oversee all corporate legal operations for Cogent Biosciences. "I am excited to welcome Evan to the Cogent team as our Chief Legal Officer," said Andrew Robbins, President and Chief Executive Officer of Cogent Biosciences. "Evan's expert counsel and proven leadership in ad

    5/3/21 7:00:00 AM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COGT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cogent Biosciences Inc.

    SC 13G/A - Cogent Biosciences, Inc. (0001622229) (Subject)

    11/14/24 7:59:55 PM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cogent Biosciences Inc.

    SC 13G/A - Cogent Biosciences, Inc. (0001622229) (Subject)

    11/14/24 5:47:15 PM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cogent Biosciences Inc.

    SC 13G/A - Cogent Biosciences, Inc. (0001622229) (Subject)

    11/14/24 4:05:10 PM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COGT
    Financials

    Live finance-specific insights

    View All

    Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

    -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib demonstrated a powerful effect on mast cell burden with 89% of patients achieving ≥50% reduction in bone marrow mast cells or clearance of aggregates – -- Bezuclastinib was very well tolerated with only 14.8% of patients requiring dose reduction and no patients requiring discontinuation due to treatment related adverse events -- -- APEX NDA submission expected in 1H 2026 – -- Cogent to host investor conference call and webcast today at 8:00 a.m. ET -- WALTHAM, Mass. and BOULDER, Colo.,

    12/8/25 7:30:00 AM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH)

    -- Bezuclastinib achieves clear clinical benefit across all symptom domains including significant improvements on 11 individual symptoms plus the most severe symptom at baseline -- -- Bezuclastinib demonstrates that reducing objective measures of disease, including serum tryptase, correlates with improvement in symptom severity; the first time this has been shown in NonAdvSM patients -- -- New 48-week data demonstrate a clear, continued deepening of symptomatic improvement over time -- -- Bezuclastinib demonstrated a favorable safety and tolerability profile supporting chronic use --  -- Granted Breakthrough Therapy Designation for bezuclastinib in October 2025; New Drug Applic

    12/6/25 9:30:00 AM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced Systemic Mastocytosis

    -- Patients treated with bezuclastinib showed a superior mean change in total symptom score at 24 weeks (-24.3 points vs. -15.4 points, -8.91 point placebo-adjusted difference; p=0.0002), compared to patients treated with placebo, establishing new benchmarks for placebo-adjusted and absolute symptomatic improvement for this patient population -- -- Bezuclastinib demonstrated a powerful effect on mast cell burden, with 87.4% of patients treated with bezuclastinib achieving at least 50% reduction in serum tryptase compared to 0% of patients treated with placebo -- -- Bezuclastinib demonstrated a favorable safety and tolerability profile supporting chronic use in this patient population -- -

    7/7/25 7:06:05 AM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care